Market Research Logo

M&A: A Nicholas Hall Report on Global OTC Mergers & Acquisitions

M&A: A Nicholas Hall Report on Global OTC Mergers & Acquisitions

With organic growth seemingly ever harder to come by, M&A has become vital to OTC players large and small. For those aiming for the very top, creativity in the multi-billion dollar deals has become the trend, with the exchange of assets becoming increasingly commonplace. But in a highly fragmented market, where the Top 3 OTC giants account for less than 15% of the playing field, there is still plenty for small and medium-sized players to tuck into – numerous smaller deals have also helped to reshape the OTC landscape in recent years. All of this, and more, can be found in this invaluable report.

Global OTC Overview

A look at the OTC market as a whole, highlighting key trends and growth factors in each region

M&A Review 2013-16

Detailed analysis of the key deals year by year on a global, regional and local level, plus a multiples table for comparing amounts paid in selected deals

Trends in M&A

Identifying trends and reviewing key lessons from past M&A

M&A at the OTC Top Table

Profiles of the world’s 20 leading OTC marketers including Bayer, GSK, J&J, Pfizer and Sanofi, featuring acquisition strategies, past M&A highlights and future direction, plus year-end 2015 sales data from Nicholas Hall’s DB6 Global OTC Database

Leading M&A Targets

100 acquisition / j-v targets from around the world, covering their strengths, notable assets and top markets, plus 2015 OTC sales, growth and leading brands

Eye on the OTC Horizon and Future of M&A

The outlook for the OTC industry and factors that will shape future M&A activity

Appendix: M&A Register 2005-16

Listing all the deals with an OTC impact, back to 2005, including a summary of the big OTC deals for each year


Overview
M&A Review 2013-16
M&A Trends
M&A at the OTC Top Table
Bayer
GlaxoSmithKline
Johnson & Johnson
Pfizer
Sanofi
RB
Procter & Gamble
Boehringer Ingelheim
Takeda
Taisho
Novartis
NBTY
Mondelez
Otsuka
China Resources 999
Valeant
Prestige Brands
Perrigo
Merck
Rohto
Leading M&A Targets
Abbott
Abdi Ibrahim
Aboca
Aché
AFT Pharma
Akorn
Amrutanjan
Angelini
APR
Arkopharma
Atrium Innovations
A&Z
Beiersdorf
Biocodex
Bionorica
Biostime
Blackmores
Blistex
BMS
Boiron
By-Health
Carma
CB Fleet
Centaur
Church & Dwight
Cifarma
Cimed
Cinfa
Clorox
Combe
Cooper
Dabur
DDD
Dompé
Dong-A
Emami Group
EMS
Engelhard
EOS Products
Eversil
Expanscience
Fancl
Gedeon Richter
Glenmark
GOJO Industries
Grupo Farma
Hainan Asia
Harbin Pharmaceutical Group
Health World
Heel
Hypermarcas
Ikeda Mohando
Jamieson
JGB
Kalbe
Konimex
Lil’ Drug Store
Matrixx
Mega Lifesciences
Merz
Midway Importing
Mölnlycke
Mommy’s Bliss
Mundipharma
Mylan
Natulab
NeilMed
Nelsons
NeoCell
Nordic Naturals
Norgine
Orkla Health (previously Axellus)
Orthomol
PharmaCare
Pharmstandard (including OTCPharm)
Picasso Candamo
Pohl Boskamp
ProPhase Labs
Queisser
Quincy Bioscience
ReNew Life
Table of Contents
Leading M&A Targets (cont.)
Ricola
Servier
Shenyang Hongyao
Sido Muncul
Similasan
Stada
Standard Homeopathic
Sun Pharma
Tecnoquímicas
Tempo
Trimb Healthcare
Unipharm
Urgo (previously Vivasanté)
Ursapharm
Vitabiotics
Walmark
Woerwag
Zambon
Zarbee’s
Eye on the OTC Horizon & Future of M&A
Appendix: M&A Register 2005-16

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report